KR20250011939A - Abca4 트랜스-스플라이싱 분자 - Google Patents
Abca4 트랜스-스플라이싱 분자 Download PDFInfo
- Publication number
- KR20250011939A KR20250011939A KR1020247041372A KR20247041372A KR20250011939A KR 20250011939 A KR20250011939 A KR 20250011939A KR 1020247041372 A KR1020247041372 A KR 1020247041372A KR 20247041372 A KR20247041372 A KR 20247041372A KR 20250011939 A KR20250011939 A KR 20250011939A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- nucleic acid
- abca4
- identity
- splicing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341665P | 2022-05-13 | 2022-05-13 | |
| US63/341,665 | 2022-05-13 | ||
| US202363478472P | 2023-01-04 | 2023-01-04 | |
| US63/478,472 | 2023-01-04 | ||
| PCT/US2023/066969 WO2023220742A2 (en) | 2022-05-13 | 2023-05-12 | Abca4 trans-splicing molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250011939A true KR20250011939A (ko) | 2025-01-22 |
Family
ID=88731152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247041372A Pending KR20250011939A (ko) | 2022-05-13 | 2023-05-12 | Abca4 트랜스-스플라이싱 분자 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240042057A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4522758A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025521102A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250011939A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119731328A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023269865A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3252043A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2634434A (cg-RX-API-DMAC7.html) |
| IL (1) | IL316944A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014029A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023220742A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250150157A (ko) | 2018-04-17 | 2025-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| KR20250011939A (ko) | 2022-05-13 | 2025-01-22 | 아시디엔 테라퓨틱스, 인크. | Abca4 트랜스-스플라이싱 분자 |
| WO2025217174A1 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv |
| WO2025217163A2 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Novel aav capsids binding to human cd59 |
| US12686869B1 (en) | 2026-01-23 | 2026-07-21 | Amber Bio Inc. | Methods and compositions for trans-splicing utilizing trifunctional elements |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0883344B2 (en) | 1995-12-15 | 2010-06-09 | VIRxSYS Corporation | Therapeutic molecules generated by trans-splicing |
| US6280978B1 (en) | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| EP0938381B1 (en) | 1996-10-04 | 2012-12-26 | Veri-Q Inc. | Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation |
| US6929907B2 (en) | 1999-12-31 | 2005-08-16 | North Carolina State University | Methods and compositions for determining the purity of chemically synthesized nucleic acids |
| CA2452690C (en) | 2001-06-29 | 2016-08-16 | Veri-Q, Inc. | Methods and compositions for determining the purity of and purifying chemically synthesized nucleic acids |
| AU2003215249B2 (en) | 2002-02-12 | 2008-07-03 | Virxsys Corporation | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US7399753B2 (en) | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
| CA2477295A1 (en) | 2002-02-25 | 2003-09-04 | Intronn, Inc. | Trans-splicing mediated imaging of gene expression |
| AU2003247505A1 (en) | 2002-06-05 | 2003-12-22 | University Of Iowa Research Foundation | Spliceosome mediated rna trans-splicing in stem cells |
| WO2003104412A2 (en) | 2002-06-05 | 2003-12-18 | Intronn, Inc. | Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling |
| US20040018622A1 (en) | 2002-07-17 | 2004-01-29 | Mitchell Lloyd G. | Spliceosome mediated RNA trans-splicing for correction of skin disorders |
| AU2003285009B2 (en) | 2002-10-23 | 2010-10-07 | Virxsys Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
| WO2005070948A1 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing |
| US7968334B2 (en) | 2004-01-23 | 2011-06-28 | Virxsys Corporation | Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing |
| WO2005070023A2 (en) | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing |
| WO2006026611A2 (en) | 2004-08-31 | 2006-03-09 | Mitchell Lloyd G | Reverse transcriptase mediated rna gene expression |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US20090214478A1 (en) | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| EP2486136B1 (en) | 2009-10-08 | 2016-03-30 | Association Institut de Myologie | Nucleic acid molecules and methods for exchanging exon(s) by transsplicing |
| US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
| US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| ES2646716T3 (es) | 2011-09-05 | 2017-12-15 | Stichting Katholieke Universiteit | Oligonucleótidos antisentido para el tratamiento de amaurosis congénita de Leber |
| CN105120901A (zh) | 2012-07-11 | 2015-12-02 | 宾夕法尼亚大学托管会 | Rpgr x染色体连锁视网膜退化的aav介导的基因治疗 |
| CN104955951A (zh) | 2012-10-16 | 2015-09-30 | 麻省理工学院 | 稳定的非多腺苷酸化rna的产生 |
| DK2986635T3 (en) | 2013-04-18 | 2019-01-28 | Fond Telethon | EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS |
| US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| LT3167076T (lt) * | 2014-07-09 | 2022-02-10 | Lexogen Gmbh | Metodai ir produktai, skirti rnr transkripto variantų kiekybiniam įvertinimui |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| AU2016355343C1 (en) * | 2015-11-19 | 2024-10-03 | Lloyd G. Mitchell | Compositions and methods for correction of heritable ocular disease |
| JP7036723B2 (ja) | 2015-12-14 | 2022-03-15 | コールド スプリング ハーバー ラボラトリー | 眼疾患の処置のための組成物および方法 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017171654A1 (en) | 2016-04-01 | 2017-10-05 | National University Of Singapore | Trans-splicing rna (tsrna) |
| US11795455B2 (en) | 2017-07-31 | 2023-10-24 | Massachusetts Institute Of Technology | RNA cleavage-induced transcript stabilizer and uses thereof |
| KR20260009385A (ko) | 2017-08-25 | 2026-01-19 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| MX2020009579A (es) * | 2018-03-15 | 2020-11-09 | Intergalactic Therapeutics Inc | Vectores de adn sintetico y metodos de uso. |
| KR20250150157A (ko) * | 2018-04-17 | 2025-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| BR112021020539A2 (pt) | 2019-04-17 | 2022-01-04 | Univ Pennsylvania | Terminador de hélice tripla para trans-splicing de rna eficiente |
| WO2020214990A1 (en) * | 2019-04-17 | 2020-10-22 | Ascidian Therapeutics, Inc. | Abca4 cell line and methods of use |
| CN113795155A (zh) * | 2019-05-01 | 2021-12-14 | 宝洁公司 | 产生短链脂肪酸的益生菌菌株和包含该益生菌菌株的组合物 |
| EP4013873A1 (en) | 2019-08-16 | 2022-06-22 | Massachusetts Institute Of Technology | Targeted trans-splicing using crispr/cas13 |
| WO2021076656A1 (en) | 2019-10-15 | 2021-04-22 | University Of Massachusetts | Rna editor-enhanced rna trans-splicing |
| EP3992292A4 (en) | 2020-02-28 | 2023-06-21 | Rznomics Inc. | APOE4 RNA-SPECIFIC TRANSSPLICING RIBOZYME AND ITS USE |
| EP4217010A4 (en) | 2020-09-28 | 2025-01-08 | Tacit Therapeutics, Inc. | TRANS-SPLICING SYSTEM FOR TISSUE-SPECIFIC REPLACEMENT OF RNA SEQUENCES |
| EP4323391A4 (en) | 2021-04-15 | 2025-04-16 | Tacit Therapeutics, Inc. | HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS |
| JP2024533163A (ja) | 2021-09-03 | 2024-09-12 | タシト・セラピューティクス・インコーポレーテッド | スプライソソーム構成要素のリクルートを介したrna編集 |
| WO2023205694A2 (en) | 2022-04-20 | 2023-10-26 | Tacit Therapeutics, Inc. | Stabilization of therapeutic trans-splicing rna molecules in human cells |
| EP4519436A4 (en) | 2022-05-03 | 2026-08-19 | Tacit Therapeutics Inc | LOCALIZATION OF NUCLEIC ACID MOLECULES TRANS-SPLICING TO AND WITHIN THE CELL NUCLEUS |
| KR20250011939A (ko) | 2022-05-13 | 2025-01-22 | 아시디엔 테라퓨틱스, 인크. | Abca4 트랜스-스플라이싱 분자 |
-
2023
- 2023-05-12 KR KR1020247041372A patent/KR20250011939A/ko active Pending
- 2023-05-12 CA CA3252043A patent/CA3252043A1/en active Pending
- 2023-05-12 GB GB2418240.4A patent/GB2634434A/en active Pending
- 2023-05-12 EP EP23804548.8A patent/EP4522758A4/en active Pending
- 2023-05-12 JP JP2024566858A patent/JP2025521102A/ja active Pending
- 2023-05-12 WO PCT/US2023/066969 patent/WO2023220742A2/en not_active Ceased
- 2023-05-12 US US18/316,959 patent/US20240042057A1/en active Pending
- 2023-05-12 CN CN202380049353.8A patent/CN119731328A/zh active Pending
- 2023-05-12 IL IL316944A patent/IL316944A/en unknown
- 2023-05-12 AU AU2023269865A patent/AU2023269865A1/en active Pending
- 2023-11-22 US US18/518,212 patent/US12410440B2/en active Active
-
2024
- 2024-11-12 MX MX2024014029A patent/MX2024014029A/es unknown
-
2025
- 2025-07-25 US US19/280,445 patent/US20260049332A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12410440B2 (en) | 2025-09-09 |
| US20240091381A1 (en) | 2024-03-21 |
| JP2025521102A (ja) | 2025-07-08 |
| IL316944A (en) | 2025-01-01 |
| GB202418240D0 (en) | 2025-01-29 |
| CA3252043A1 (en) | 2023-11-16 |
| WO2023220742A2 (en) | 2023-11-16 |
| EP4522758A2 (en) | 2025-03-19 |
| WO2023220742A3 (en) | 2024-03-28 |
| US20240042057A1 (en) | 2024-02-08 |
| GB2634434A (en) | 2025-04-09 |
| US20260049332A1 (en) | 2026-02-19 |
| EP4522758A4 (en) | 2026-05-06 |
| AU2023269865A1 (en) | 2024-11-21 |
| CN119731328A (zh) | 2025-03-28 |
| MX2024014029A (es) | 2025-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11969478B2 (en) | Optimized RPE65 promoter and coding sequences | |
| US12410440B2 (en) | ABCA4 trans-splicing molecules | |
| US11993776B2 (en) | Trans-splicing molecules | |
| CN110191954B (zh) | 用于治疗涉及rdh12的病症和疾病的方法和组合物 | |
| AU2016355343A1 (en) | Compositions and methods for correction of heritable ocular disease | |
| US20220175969A1 (en) | Enhanced human opsin promoter for rod specific expression | |
| JP2023116709A (ja) | 眼疾患のための遺伝子療法 | |
| CA3096088A1 (en) | Compositions and methods for treating macular dystrophy | |
| JP2025534371A (ja) | Opa1遺伝子変異に関連付けられる疾患を治療するためのopa1プレメッセンジャーrnaのトランススプライシングによる療法 | |
| WO2025247393A1 (zh) | 用于治疗Prom1相关视网膜疾病的新型治疗药物 | |
| EP4656244A2 (en) | Gene therapy for ocular disorders | |
| EP3630986B1 (en) | Gene therapy for treating peroxisomal disorders | |
| CN116334141A (zh) | 基于基因编辑的RHO-R135W-adRP基因编辑药物 | |
| JP2024522072A (ja) | 視覚機能を増強するための組成物及び方法 | |
| EP3998086A1 (en) | Therapeutic agent for disease caused by dominant mutant gene | |
| WO2024069144A1 (en) | Rna editing vector | |
| JP2021520231A (ja) | シュタルガルト病の処置のための組成物及び方法 | |
| US20250108129A1 (en) | Exon skipping to treat Usher Syndrome | |
| WO2025106562A1 (en) | Mecp2 trans-splicing molecules | |
| WO2026045773A1 (zh) | Prpf31突变引起的视网膜色素变性的基因治疗 | |
| CN121674478A (zh) | 一种用于prpf31基因治疗药效及安全性评价的小鼠模型 | |
| WO2026039524A1 (en) | Msh3 modulatory molecules | |
| WO2024108055A1 (en) | Methods for treating cep290 associated disease | |
| HK40093831A (en) | Rho-r135w-adrp gene editing drug based on gene editing | |
| CN117337331A (zh) | 用于增强视觉功能的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |